Key Stats
Key stats represent essential financial metrics and indicators used to evaluate a company's performance and potential investment opportunities.
Stock Score/grades
The Stock Score/Grades evaluate bankruptcy risk and assess the financial strength and fundamental health of a company
- Altman Z Score 3.04
- Piotroski Score 5.00
- Grade Overweight
- Symbol (TXG)
- Company 10x Genomics, Inc.
- Price $14.29
- Changes Percentage (7.52%)
- Change $1
- Day Low $12.98
- Day High $14.57
- Year High $57.90
10x Genomics, Inc., a life science technology company, develops and sells instruments, consumables, and software for analyzing biological systems in North America, Europe, the Middle East, Africa, China, and the Asia Pacific. The company provides chromium and chromium connect instruments, microfluidic chips, slides, reagents, and other consumables products. Its single cell solutions runs on its chromium instruments, which include single cell gene expression for measuring gene activity on a cell-by-cell basis; single cell immune profiling for measuring the activity of immune cells and their targets; single cell Assay for Transposase Accessible Chromati (ATAC) for measuring epigenetics comprising the physical organization of DNA; and single cell multiome ATAC + gene expression for measuring the genetic activity and epigenetic programming in the same cells across tens of thousands of cells in a single experiment. The company also provides visium spatial gene expression solution for measuring spatial gene expression patterns across a single tissue sample or gene expression and protein co-detection when combined with immunofluorescence. It serves various academic, government, biopharmaceutical, biotechnology, and other institutions. The company was formerly known as 10X Technologies, Inc. and changed its name to 10x Genomics, Inc. in November 2014. 10x Genomics, Inc. was incorporated in 2012 and is headquartered in Pleasanton, California.
- Last Earnings
- Ex-Dividend for 5/16 Dividend
- Dividend Payable
- Today N/A
- Next Earnings (Estimated) 02/13/2025
- Fiscal Year End N/A
- Average Stock Price Target $25.00
- High Stock Price Target $46.00
- Low Stock Price Target $24.00
- Potential Upside/Downside N/A
- Consensus Rating Strong Sell
- Rating Score (0-4) N/A
- Research Coverage N/A
- EPS (Most Recent Fiscal Year) -$2.24
- Trailing P/E Ratio -9.76
- Forward P/E Ratio -9.76
- P/E Growth -9.76
- Net Income $-255,099,000
Income Statement
Quarterly
Annual
Latest News of TXG
The Latest News section aggregates recent news posts from various news outlets, offering a comprehensive overview of the most recent developments related to the topic.
-
TX Group's (VTX:TXGN) Returns On Capital Tell Us There Is Reason To Feel Uneasy
As businesses mature, declining Return on Capital Employed (ROCE) and capital employed indicate diminishing shareholder wealth. For TX Group, ROCE is at 2.0%, below the industry average of 9.3%. Despi...
By Yahoo! Finance | 1 week ago -
10x Genomics Inc (TXG) Q3 2024 Earnings Call Highlights: Navigating Challenges with Strategic ...
Adam Taich, CFO, indicated that revenue guidance cut was influenced by macroeconomic factors and internal commercial reorganization. The company expects stable gross margins with new products and aims...
By Yahoo! Finance | 3 weeks ago -
TX Group's (VTX:TXGN) Earnings Are Weaker Than They Seem
Despite strong earnings, TX Group AG's stock performance was lackluster due to underlying concerns. Unusual gains contributed to profits, but may not be sustainable. Analysts' future profit forecasts ...
By Yahoo! Finance | 2 months ago
